Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $17.00.

Several equities research analysts have recently commented on TEVA shares. Barclays upped their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, June 5th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. Piper Sandler reiterated an “overweight” rating and set a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a research note on Friday, March 8th. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, May 30th.

Teva Pharmaceutical Industries Stock Up 0.5 %

Teva Pharmaceutical Industries stock opened at $16.33 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $7.42 and a 52 week high of $17.69. The stock has a market cap of $18.50 billion, a price-to-earnings ratio of -39.83, a PEG ratio of 1.54 and a beta of 0.90. The company’s 50-day moving average price is $16.06 and its two-hundred day moving average price is $13.75. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. On average, analysts expect that Teva Pharmaceutical Industries will post 2.32 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the sale, the chief accounting officer now owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders sold a total of 549,719 shares of company stock worth $9,353,736 in the last 90 days. 0.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently added to or reduced their stakes in the stock. Lingotto Investment Management LLP grew its position in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after acquiring an additional 607,800 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after acquiring an additional 2,188,212 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after purchasing an additional 1,860,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 3.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 28,533,099 shares of the company’s stock worth $297,886,000 after buying an additional 821,759 shares during the last quarter. Finally, Rubric Capital Management LP raised its position in shares of Teva Pharmaceutical Industries by 1.5% during the 3rd quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $193,800,000 after acquiring an additional 281,638 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.